Press Release

Qualcomm and Boehringer Ingelheim Pharmaceuticals collaborate to add new digital technology to RESPIMAT® inhaler

-- Two industry leaders combine strengths in health care and technology to aim to improve chronic obstructive pulmonary disease (COPD) care –

30 Ags 2016SAN DIEGO

Qualcomm products mentioned within this press release are offered by Qualcomm Technologies, Inc. and/or its subsidiaries.

Boehringer Ingelheim Pharmaceuticals Inc. and Qualcomm Incorporated (NASDAQ: QCOM) through its subsidiary, Qualcomm Life, Inc., today announced a new collaboration to develop a connectivity solution for the RESPIMAT inhaler, the platform inhaler for the Boehringer Ingelheim family of respiratory therapies, to help improve COPD treatment outcomes. The collaboration will be announced at Qualcomm Life’s fifth annual Connect 2016 ecosystem conference, taking place on August 30 and August 31, 2016 in San Diego, California.

“For more than 40 years, Boehringer Ingelheim has had an unwavering commitment to the COPD community to provide new health solutions that can help improve patient outcomes and expand our understanding of COPD,” said Ruchin Kansal, Executive Director and Head, Business Innovation, Boehringer Ingelheim Pharmaceuticals, Inc. “Boehringer Ingelheim is proud to join forces with Qualcomm Life, a global leader in wireless technologies, to bring the latest technology to our RESPIMAT inhaler with the goal of improving adherence to daily medicines that treat symptoms of COPD.”

“Qualcomm Life is committed to powering the Internet of Medical Things to ultimately enable intelligent care to be delivered wherever the patient may be,” said Rick Valencia, president, Qualcomm Life, Inc. “We are excited to be collaborating with an industry leader like Boehringer Ingelheim to deliver a more seamless digital health experience that can enable their COPD patients to better manage their disease.”

Through its 2net™[i] Design platform, Qualcomm Life is developing the prototype for a small, wireless, low-power, disposable module for the RESPIMAT inhaler. This fully-integrated inhaler, which is designed to seamlessly connect with Qualcomm Life’s 2net Platform, will be able to track puffs from the RESPIMAT inhaler, and the collected information can be shared with health care providers and people who have been prescribed one of Boehringer Ingelheim’s RESPIMAT medicines.

As with other chronic diseases, poor adherence to treatment plans is common among people with COPD and can result in increased rates of COPD symptoms, health care costs, hospitalizations and even death. The collaboration seeks to combine Boehringer Ingelheim’s global leadership in discovering and developing COPD medicines with Qualcomm Life’s expertise in developing reference designs for wireless, single-use and small integrated modules to create a solution to support adherence to daily treatment regimens.

The RESPIMAT is the platform inhaler for the Boehringer Ingelheim respiratory medications. For more information about the RESPIMAT inhaler and the medicines approved for use in the RESPIMAT, please visit www.us.respimat.com.  

Leveraging Qualcomm Life’s deep wireless expertise and technologies, 2net Design is a platform for designing the communications components of connected medical devices, including disposable drug delivery devices and disposable diagnostic devices for condition specific connected therapies.

 

Qualcomm Contacts

Emily Kilpatrick

1-858-845-5959

John Sinnott

Investor Relations

1-858-658-4813

Related Press Releases

Press Releases

Philips and Qualcomm announce strategic collaboration to advance personalized connected health care

Royal Philips (NYSE: PHG; AEX: PHIA) and Qualcomm Incorporated (NASDAQ: QCOM) through its subsidiary, Qualcomm Life, Inc., today announced a strategic technology collaboration to advance connected health across the health continuum -- from healthy living and prevention to chronic care management and home care. The companies are teaming up to leverage each other’s respective leading capabilities – Philips’ leadership in connected health informatics and regulated health care cloud data management and analytics, and Qualcomm Life’s expertise in secure, medical-grade device connectivity and integration. This collaboration will enable both companies to offer care providers enhanced, scalable, connected care solutions and services within a secure global ecosystem.

Qualcomm Life’s 2net Platform will serve as the medical device connectivity solution for Philips HealthSuite, the company’s cloud-enabled health ecosystem of devices, apps and digital tools. By joining the Qualcomm Life 2net Ecosystem, Philips provides its HealthSuite users seamless access to a wide array of connected medical devices including medication dispensers, medical grade biosensors, ventilators, blood pressure monitors, point of care self-tests, and blood glucose meters. Philips will leverage the 2net Platform to connect both Philips and third party medical devices. Secure connectivity, data capture and transmission powered by the 2net Platform, 2net Hub and 2net Mobile, will enable HealthSuite users to customize and scale connected care programs, add additional medical devices and gain a fuller patient profile over longer periods of time, with the aim to support timely intervention, assist in diagnosis, personalize treatment plans and help contribute to the goal of improving patient outcomes. An example of an implementation of this connectivity collaboration will go live shortly with Philips’ Trilogy ventilator family and Care Orchestrator care management application to advance care for patients with COPD and other respiratory conditions.

As part of the collaboration, Qualcomm Life will leverage Philips HealthSuite as a global, secure, data management and storage solution for its medical-grade 2net Platform, allowing Qualcomm Life to tap into the value of health data through data normalization, aggregation and analytics. Qualcomm Life customers can now have direct access to build applications, integrate with electronic health record systems, store normalized data, run analytics, and manage authorization and consents in a compliant and secure environment. 

“As the home is fast becoming a viable care setting, care providers, home health agencies, and other institutions are increasingly using connected care to reduce emergency care, readmissions of patients with chronic diseases,” said Jeroen Tas, CEO, Connected Care and Health Informatics at Philips. “By collaborating with Qualcomm Life and leveraging its connectivity and wireless expertise, we aim to help care providers to engage better with their patients and contribute to the goal of improving outcomes. Patient self-management combined with 24/7 connectivity to a care network is an emerging model that enables scalable chronic disease management for patients and providers.”

“An undeniable leader in the health care technology industry, Philips brings a deep technology expertise to their health care initiatives, and by joining forces we aim to deliver intelligent care to patients and providers at scale,” said Rick Valencia, president, Qualcomm Life, Inc. “We are thrilled to be working with Philips, enabling Qualcomm Life to continue to grow its ecosystem and ultimately serve as the underpinning of the Internet of Medical Things.”

Jeroen Tas and Rick Valencia will deliver keynote presentations at Qualcomm Life’s connected health ecosystem conference, Connect 2016, on August 31, in San Diego, CA. For more information please visit http://www.qualcommlife.com/connect/ and follow @PhilipsLiveFrom, @QualcommLife and the event hashtag, #qualcommconnect.

For more information on Philips HealthSuite, please visit: http://www.usa.philips.com/healthcare/innovation/about-health-suite.

For more information on Qualcomm Life 2net, please visit: http://www.qualcommlife.com/mobile-medical-solutions.

31 Ags 2016
Press Releases

Qualcomm and Boehringer Ingelheim Pharmaceuticals collaborate to add new digital technology to RESPIMAT® inhaler

Boehringer Ingelheim Pharmaceuticals Inc. and Qualcomm Incorporated (NASDAQ: QCOM) through its subsidiary, Qualcomm Life, Inc., today announced a new collaboration to develop a connectivity solution for the RESPIMAT inhaler, the platform inhaler for the Boehringer Ingelheim family of respiratory therapies, to help improve COPD treatment outcomes. The collaboration will be announced at Qualcomm Life’s fifth annual Connect 2016 ecosystem conference, taking place on August 30 and August 31, 2016 in San Diego, California.

“For more than 40 years, Boehringer Ingelheim has had an unwavering commitment to the COPD community to provide new health solutions that can help improve patient outcomes and expand our understanding of COPD,” said Ruchin Kansal, Executive Director and Head, Business Innovation, Boehringer Ingelheim Pharmaceuticals, Inc. “Boehringer Ingelheim is proud to join forces with Qualcomm Life, a global leader in wireless technologies, to bring the latest technology to our RESPIMAT inhaler with the goal of improving adherence to daily medicines that treat symptoms of COPD.”

“Qualcomm Life is committed to powering the Internet of Medical Things to ultimately enable intelligent care to be delivered wherever the patient may be,” said Rick Valencia, president, Qualcomm Life, Inc. “We are excited to be collaborating with an industry leader like Boehringer Ingelheim to deliver a more seamless digital health experience that can enable their COPD patients to better manage their disease.”

Through its 2net™[i] Design platform, Qualcomm Life is developing the prototype for a small, wireless, low-power, disposable module for the RESPIMAT inhaler. This fully-integrated inhaler, which is designed to seamlessly connect with Qualcomm Life’s 2net Platform, will be able to track puffs from the RESPIMAT inhaler, and the collected information can be shared with health care providers and people who have been prescribed one of Boehringer Ingelheim’s RESPIMAT medicines.

As with other chronic diseases, poor adherence to treatment plans is common among people with COPD and can result in increased rates of COPD symptoms, health care costs, hospitalizations and even death. The collaboration seeks to combine Boehringer Ingelheim’s global leadership in discovering and developing COPD medicines with Qualcomm Life’s expertise in developing reference designs for wireless, single-use and small integrated modules to create a solution to support adherence to daily treatment regimens.

The RESPIMAT is the platform inhaler for the Boehringer Ingelheim respiratory medications. For more information about the RESPIMAT inhaler and the medicines approved for use in the RESPIMAT, please visit www.us.respimat.com.  

Leveraging Qualcomm Life’s deep wireless expertise and technologies, 2net Design is a platform for designing the communications components of connected medical devices, including disposable drug delivery devices and disposable diagnostic devices for condition specific connected therapies.

 

30 Ags 2016